Header image
![](/sites/default/files/styles/page_header_image/public/2023-07/foto_zahlavi_research_1.jpg?itok=p7pBtlZR)
Impact Factor Journals
The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.
Journal of Nuclear Medicine.
2023,
ISSN: 0161-5505,
PMID: 37770110.
The isocyanide SN2 reaction.
Nature Communications.
2023,
14(1),
5807,
ISSN: 2041-1723,
IF: 16.6,
PMID: 37726293.
Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells.
European Journal of Medicinal Chemistry.
2023,
261,
115790,
ISSN: 0223-5234 ,
PMID: 37690264,
A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarcinoma.
Carcinogenesis.
2023,
ISSN: 0143-3334,
PMID: 37670727,
Circulating tumor cell-derived preclinical models: current status and future perspectives.
Cell Death & Disease.
2023,
14(8),
530,
ISSN: 2041-4889,
PMID: 37591867,
Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors.
Journal of Medicinal Chemistry.
2023,
66(14),
9577-9591,
ISSN: 0022-2623,
PMID: 37450644,